Profasi

Quick links to important sections

Profasi

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Profasi

What is Profasi?

Profasi is a medication containing human chorionic gonadotropin (hCG), a hormone that supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation.

Mechanism of Action

In the female body, this hormone acts similarly to luteinizing hormone (LH). LH is naturally produced by the pituitary gland and plays a critical role in the reproductive cycle by triggering ovulation and supporting the maintenance of the corpus luteum. By mimicking this natural surge, Profasi helps facilitate the final maturation of the follicles.

In males, hCG stimulates the Leydig cells in the testes to produce androgens, such as testosterone. This process is essential for the development of secondary sexual characteristics and the support of sperm production.

Therapeutic Use

Profasi is primarily utilized in the field of reproductive medicine. It is commonly used as part of fertility treatments for individuals who require hormonal assistance to achieve conception.

For women, it is often used in conjunction with other medications that stimulate follicle growth. Once the follicles have reached an appropriate size, Profasi is administered to induce the final stage of egg maturation and subsequent release.

In men, it may be used to address certain types of hormonal imbalances that affect testosterone production and testicular function. It is also used in specific pediatric cases to treat cryptorchidism, a condition where the testes have not descended normally into the scrotum, provided the condition is not caused by a physical obstruction.

Regulatory References

  1. MedlinePlus - Pregnancy test

What side effects are possible with Profasi?

Possible Side Effects and Safety Information

The safety profile of Profasi (Chorionic Gonadotropin) is defined by officially documented adverse reactions classified by frequency and the body system affected, consistent with regulatory reporting standards such as those used by the FDA and EMA.

Adverse Reaction Classifications

Side effects are categorized based on their official regulatory frequency. Common adverse reactions, defined as those occurring in up to 1 in 10 patients, include headache, fatigue, irritability, depression, restlessness, and local reactions such as pain or swelling at the injection site. Other effects classified as Common include edema (fluid retention) and gynecomastia (breast enlargement) in males.

System-Organ Class (SOC) Documented Adverse Reactions (Examples)
Nervous/Psychiatric Disorders Headache, Irritability, Depression, Restlessness
General/Admin Site Fatigue, Edema, Local Injection Site Pain/Swelling
Reproductive System Ovarian Hyperstimulation Syndrome (OHSS), Gynecomastia
Vascular Disorders Arterial Thromboembolism

Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reaction officially documented is Severe Ovarian Hyperstimulation Syndrome (OHSS), which is classified as uncommon. The risk for OHSS is noted in labeling as being greatest immediately following administration and in the subsequent two weeks. The risk of Arterial Thromboembolism is also documented as a rare but serious adverse event.

Safety constraints (contraindications) prohibit use in individuals with known hypersensitivity to hCG, pre-existing sex hormone-dependent tumors (such as prostate carcinoma), and primary ovarian or testicular failure. Furthermore, specific safety considerations are documented for prepubertal boys regarding the potential for precocious puberty and early epiphyseal closure, as listed in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Profasi (Chorionic Gonadotropin) addresses the risk of an excessive hormonal response, which can lead to severe and potentially life-threatening complications, primarily Ovarian Hyperstimulation Syndrome (OHSS).

Documented Manifestations Requiring Urgent Care

Classification Signs and Symptoms
Severe OHSS Severe pelvic or abdominal pain, rapid weight gain (more than 2.2 pounds/1 kg in 24 hours), severe nausea/vomiting, decreased urination (oliguria), and shortness of breath [1.1, 2.6].
Life-Threatening Events Signs of a thromboembolic reaction (blood clot) or cardiovascular shock secondary to fluid shifts [1.3, 2.6].

Required Emergency Actions

The regulatory documents explicitly require immediate action upon recognition of severe symptoms:

  • Seek Immediate Medical Attention: Individuals experiencing signs of severe OHSS, a blood clot, or an acute pulmonary condition must seek emergency medical attention or call emergency services right away [1.1, 2.4].
  • Withholding Medication: If evidence suggests that OHSS is developing, the administration of Profasi must be withheld [2.6].

Supportive Measures and Population Notes

  • Antidote Status: No specific antidote is known for Profasi; treatment for severe complications is officially designated as primarily symptomatic and supportive [2.6].
  • Monitoring: Hospital monitoring and close observation are required for serious OHSS [2.6].
  • Pediatric Warning: In prepubertal males, an over-response may induce precocious puberty; regulatory documents mandate that therapy should be discontinued if these signs occur [2.4, 3.4].

The overdose profile is defined by these severe, documented complications and the mandatory emergency actions they trigger, focusing on symptomatic management and immediate professional medical intervention.

Therapeutic Uses of Profasi

Quick Facts

  • May assist with the induction of ovulation in certain women with infertility.
  • Used in the management of male hypogonadism.
  • May be utilized to promote the descent of testes in young males with prepubertal cryptorchidism.

Profasi (human chorionic gonadotropin or hCG) is a therapeutic agent used in a clinical context to address certain reproductive health challenges. In women, the medication may be administered to assist with the induction of ovulation and is indicated for the treatment of anovulatory infertility in select patients who have been appropriately prepared with other treatments. This application aims to support the normal development of the egg and trigger its release.

For male patients, Profasi may be used as an important component in the management of hypogonadotropic hypogonadism, a condition characterized by low levels of specific sex hormones. Its use in males may help stimulate the testes to support the development of secondary sex characteristics. Additionally, the drug may be utilized in prepubertal males to promote the descent of one or both testes in cases of cryptorchidism that are not caused by an anatomical obstruction.

Eligibility and Restrictions for Use

The official regulatory profile for Profasi (Chorionic Gonadotropin) strictly defines who is eligible for treatment. The medication is authorized for use in infertile women with specific types of anovulation, males with hypogonadotropic hypogonadism, and prepubertal males with non-obstructive cryptorchidism.

Contraindicated Populations

Profasi is contraindicated and must not be used by several population groups. These absolute exclusions include individuals with a known hypersensitivity to the drug, patients diagnosed with sex hormone-dependent neoplasms (such as certain ovarian, prostate, or breast tumors), existing precocious puberty, active thromboembolic disorders, and women who are currently pregnant. The drug is also prohibited in cases of primary gonadal failure.

Restricted and Non-Established Use

Use is restricted in certain populations requiring close supervision:

  • Caution is required for patients with cardiac or renal disease, epilepsy, migraine, or asthma, due to the potential risk of fluid retention.
  • Safety and effectiveness are formally not established for children under the age of four years or for geriatric patients aged 65 and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Profasi, whose active component is Chorionic Gonadotropin, is classified as a glycoprotein hormone. Its official regulatory profile for interactions is distinct from that of small-molecule synthetic drugs. The interaction information found in authoritative government-issued prescribing documents is characterized by the absence of specific, formally documented interaction entities with other medicinal products, foods, or substances.

Interaction Category Official Regulatory Documentation Statement
Pharmacokinetic (PK) Interactions None documented. Interactions affecting drug metabolism (CYP enzymes) or transporters are not specified.
Pharmacodynamic (PD) Interactions None documented. No additive or synergistic effects with other medicinal products are listed.
Contraindications None documented. No specific substances are listed as contraindicated due to an interaction risk.
Timing Requirements None documented. No mandatory dose separation times are required based on interaction rules.

Official labeling from regulatory bodies, such as the FDA and EMA, does not contain a list of interacting medicines or product classes. Consequently, there are no formal prohibitions or restrictions on co-administration based on a documented interaction mechanism. This profile is consistent with the hormone’s elimination pathways, which do not rely on the common metabolic systems or drug transporters typically responsible for causing drug-drug interactions. Regulatory documents do not specify any compounds that alter Profasi's systemic exposure or clearance.

Mechanism of Action

Agonism of the Luteinizing Hormone/Choriogonadotropin Receptor

Profasi, which contains human chorionic gonadotropin (hCG), exerts its action by binding to and activating the Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR), a G-protein coupled receptor expressed primarily on gonadal cells. This interaction defines its primary biological target and establishes its role as an LHCGR agonist, mimicking the effect of endogenous luteinizing hormone (LH).


Gonadal Steroidogenesis Stimulation

Activation of the LHCGR initiates an intracellular signaling cascade, primarily involving cyclic adenosine monophosphate (cAMP) as a second messenger. This pathway modulation triggers the enzymatic sequence required for the synthesis and secretion of gonadal steroid hormones. This includes progesterone release from the ovarian corpus luteum and testosterone production by testicular Leydig cells.


Modulation of Ovarian and Testicular Functional Responses

Through the downstream effects of elevated steroidogenesis, Profasi modulates specific system-level physiological consequences. In the ovary, it modifies follicular wall integrity and drives the transition to the luteal phase. In the testes, it acts to regulate germ cell maturation sequences and promote subsequent androgen production by the Leydig cells.

Dosage and Administration Information

Administration Overview

Profasi is typically administered through injection. The process involves preparing the solution and ensuring the correct technique is used for either subcutaneous or intramuscular delivery. The specific method of administration is determined based on the clinical requirement and the guidance provided by a healthcare professional.

Preparation of the Solution

The medication often comes in a powder form that requires reconstitution with a sterile diluent.

  • Inspection: Before use, the powder and the diluent should be checked for any discoloration or particulate matter.
  • Mixing: The diluent is added to the powder vial gently. It is important to swirl the vial slowly rather than shaking it to ensure the powder dissolves completely without creating excessive foam.
  • Withdrawal: Once the solution is clear, it is drawn into the syringe for immediate use.

Injection Process

The injection site should be rotated regularly to minimize discomfort or tissue irritation. Common sites include the upper thigh or the abdomen, depending on the chosen injection method.

  • Site Preparation: The skin at the injection site is cleaned thoroughly before the needle is inserted.
  • Technique: The needle is inserted at the appropriate angle to ensure the medication reaches the intended tissue layer. Once the medication is injected, the needle is removed, and light pressure may be applied to the site.

Handling and Storage

Proper maintenance of the medication is essential for its stability.

  • Storage: The product should be kept in a cool environment, away from direct light and heat.
  • Disposal: Used syringes and needles must be placed in a puncture-resistant container to ensure safe disposal and prevent accidental injury.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Profasi

Evidence for Use in Ovulation Induction (Female Infertility)

The role of the active ingredient in Profasi, Chorionic Gonadotropin (hCG), in female infertility is primarily supported by short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies focused on women with specific types of anovulatory infertility. The research examined the medication's role in the final maturation and release of the egg, a necessary step for ovulation.

In these trials, researchers monitored several outcomes related to systemic or functional imbalance, including the final maturation of the egg and clinical pregnancy rates. The research contributes to understanding symptom patterns observed during the maturation event. However, the current body of evidence offers limited information for long-term outcomes, particularly the cumulative live birth rates across multiple treatment cycles.

Evidence for Use in Male Hypogonadotropic Hypogonadism

Research has explored the use of this hormone in adult males diagnosed with hypogonadotropic hypogonadism, a condition marked by functional limitations related to sex hormone production. The available evidence includes prospective, non-randomized studies conducted over intermediate to long periods. The research examined outcomes related to systemic or functional imbalance, such as changes in serum testosterone concentration, increases in testicular volume, and the initiation or maintenance of spermatogenesis (sperm production).

Findings report how symptoms evolved in the observed populations. Data show patterns related to what was observed when the hormone was administered. A primary limitation is that many of these studies rely on surrogate markers (like sperm count and hormone levels) rather than providing conclusive, consistent data on final outcomes, such as live birth rates. Also, follow-up durations were limited in some trials, meaning the long-term effects are not fully established.

Gaps in Research and Areas of Uncertainty

A persistent gap across all indications is the limited information available on long-term outcomes that track patients for several years following treatment. For prepubertal cryptorchidism, the evidence quality varies across studies, and findings were mixed, contributing to low certainty in its overall consensus compared to surgical alternatives. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

  1. Effect of Gonadotropin Therapies in Adolescent Males with Hypogonadotropic Hypogonadism: Meta-Analysis
  2. Evaluation of Human Chorionic Gonadotropin (HCG) Therapeutic Results in Patients With Unilateral cryptorchidism (Undescended Testis)

Frequently Asked Questions (FAQ)

Common questions about Profasi (FAQ)


Q: What are the signs of a severe reaction to Profasi?

Severe adverse reactions are officially documented and are described as requiring immediate evaluation by a healthcare provider. Signs of a severe allergic reaction (anaphylaxis) may involve hives, swelling of the face or throat, or trouble breathing. Severe Ovarian Hyperstimulation Syndrome (OHSS) is an important documented risk that may involve symptoms such as severe pelvic pain, rapid weight gain, or shortness of breath.


Q: How long after taking Profasi do the effects begin?

According to official product information on pharmacokinetics, the active ingredient's concentration in the bloodstream typically peaks within approximately six hours following an intramuscular injection. The duration of its primary biological activity is often described as lasting about 36 hours in the body, which relates to its role in reproductive processes.


Q: How quickly is Profasi cleared from the body?

The active ingredient in Profasi is cleared from the body in two distinct phases, as noted in official pharmacokinetic data. The initial elimination half-life is approximately 6 to 11 hours. A slower, terminal elimination phase takes approximately 23 to 37 hours.


Q: Does Profasi affect sleep?

The official safety profile for the medicine includes reports of nervous system disorders such as 'trouble sleeping' and 'insomnia' as documented adverse events. However, official regulatory information indicates that the reported frequency of these particular side effects is not classified as common.


Q: Are there any food interactions with Profasi?

Authoritative regulatory documents for Profasi do not specify any formally documented interactions with food or specific dietary products. Consequently, official documentation does not list any mandatory prohibitions regarding food consumption based on a documented interaction mechanism.


Q: Does smoking affect Profasi?

Official drug labeling and product information do not list smoking or tobacco use as a specific documented interaction with Profasi. Therefore, there is no formal restriction related to smoking based on affecting the medicine's systemic clearance.


Q: Is Profasi a controlled substance?

Profasi is a specialized, prescription-only injectable medication classified as a gonadotropin and a biologic product. It is not listed as a Schedule I-V controlled substance by government regulatory agencies that govern narcotics and addictive substances.


Q: Can Profasi cause vision changes?

Vision changes have been listed as an adverse event in some official regulatory reports associated with the use of the medicine. However, the incidence (how frequently these reactions occur in the population) is not formally established in official documents.


Q: What kind of professional is best qualified to monitor Profasi use?

Official documents advise that this medicine should only be used under the supervision of physicians and healthcare professionals. These professionals should have specific expertise and experience in managing conditions such as infertility and hypogonadism.


Q: How often is Profasi typically given?

The administration schedule for Profasi is determined by the specific medical condition being addressed and the patient's individual treatment protocol. For instance, in female fertility treatment, official documents describe it as typically given as a single injection 24 to 48 hours after prior ovarian stimulation.


Q: What should I do if the Profasi powder looks a different color than usual?

Official product information describes the unreconstituted powder as a white or off-white substance. If the powder appears discolored, shows signs of damage, or contains particles, the product should not be used. Consultation with the accompanying packaging instructions is advised if the appearance is abnormal.


Q: How does Profasi relate to the natural hormones in the body?

Profasi is classified as a glycoprotein hormone that is functionally similar to the body's natural Luteinizing Hormone (LH). Its mechanism is to mimic the essential actions of LH by binding to and stimulating the same hormone receptors in the reproductive system.


Q: What should I know about allergy risks associated with Profasi?

Official information states that the medicine is contraindicated (prohibited) in individuals who have a known hypersensitivity or severe allergy to the drug or its components. Serious allergic reactions, such as anaphylaxis, are documented as potential, though generally rare, risks.


Q: What documentation is available regarding the original clinical trials for Profasi?

Official regulatory documents, such as the FDA labeling and the EMA summary, contain detailed summaries of the clinical trials and research evidence that led to the drug's approval. Additional information on ongoing or recently completed research studies is generally available on public repositories like ClinicalTrials.gov.


Q: Can Profasi be used in IVF treatments?

Yes, the active ingredient in Profasi is a key component used in controlled ovarian stimulation protocols. These protocols are commonly involved in assisted reproductive technologies (ART), including In Vitro Fertilization (IVF).


Q: Do studies suggest Profasi is suitable for people with kidney problems?

Official safety information advises that patients with kidney (renal) disease should use this medicine with caution. This is primarily due to the potential risk of fluid retention (edema), which is noted as a documented adverse effect. Safety and effectiveness evidence are not formally established across the entire spectrum of this specific patient population.


Q: Why do some forums discuss Profasi for boosting testosterone?

The official regulatory indication for Profasi in adult men is for the treatment of hypogonadotropic hypogonadism. In this role, the medication is known to stimulate specific testicular cells (Leydig cells) to promote the production of androgens, which include testosterone.


Q: What are the potential effects of Profasi during pregnancy?

The use of Profasi is prohibited (contraindicated) in women who are currently pregnant. Official regulatory information states that the medicine could be fatal to the unborn fetus if it is administered after conception has already occurred.


Q: What should I know about Profasi use in elderly populations?

Official regulatory documents state that the safety and effectiveness of the medicine have not been formally established for use in geriatric patients aged 65 years and older. Regulatory documents indicate that information is limited regarding the use of this medicine in this population.


Q: What is the latest research saying about Profasi's long-term effects?

Official summaries of research evidence consistently note a persistent gap in the available data regarding long-term outcomes. This indicates that information is limited regarding the long-term outcomes and full effects of the medicine after several years of follow-up.


Q: Are there any non-medical uses commonly associated with Profasi?

Official government and health authorities have issued consumer warnings against using the active ingredient in Profasi for unauthorized or unapproved non-medical purposes. This includes over-the-counter weight-loss regimens and certain uses in athletics.


Q: What happens if I miss a scheduled dose of Profasi?

Regulatory information indicates that if a scheduled dose of the medicine is missed, patients are directed to contact their treating physician for further instructions. This is necessary to receive guidance tailored to their individual treatment plan and timing.


Q: How does Profasi differ from other fertility treatments?

Profasi is classified as a gonadotropin, meaning it acts like the body's natural Luteinizing Hormone (LH) and is primarily used as a final trigger to induce ovulation. Other common fertility treatments, such as Follicle Stimulating Hormone (FSH), work differently by stimulating the development and maturation of ovarian follicles.


Q: Can Profasi affect the results of a home pregnancy test?

Yes, Profasi contains the hormone human chorionic gonadotropin (hCG), which is the exact hormone detected by standard home pregnancy tests. Because of this, using the medicine can lead to a false-positive result on a pregnancy test.


Q: What does the term 'trigger shot' mean in relation to Profasi?

The term "trigger shot" is commonly used to describe the function of Profasi in controlled ovarian stimulation protocols. In this context, it provides the necessary hormonal signal, mimicking the natural LH surge, to trigger the final maturation and release of an egg (ovulation).

How should Profasi be stored and disposed of?

The storage and disposal of Profasi (Chorionic Gonadotropin) are subject to official regulatory requirements to maintain product integrity and ensure safe handling.

Required Storage Conditions

Product State Temperature Requirement Stability Constraint
Unreconstituted Powder & Diluent Controlled Room Temp (20 C to 25 C / 68 F to 77 F) Store in original container.
Reconstituted Solution Refrigerated (2 C to 8 C / 36 F to 46 F) Use within 60 days; Do not freeze

All forms of the medicine must be kept out of the reach of children and pets. The contents must not be shaken during preparation, and the solution must be visually inspected before use.

Disposal Instructions

Used needles, syringes, and injection vials must be placed immediately into an FDA-cleared sharps disposal container; they must not be thrown away in household trash or flushed. The sealed sharps container and any unused or expired product must be disposed of according to local and state regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Profasi found in:

A-Z Index: